AudioScholar Rheumatology Weekly

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning when and how to step ba… This week's papers: 1. Outcomes of Tapering Biologic and Targeted Synthetic DMARDs in Rheumatoid Arthritis: A Multicenter Randomized Non-Inferiority Trial. — Arthritis & Rheumatology 2026 2. Comparative efficacy and safety of disease-modifying antirheumatic drugs tapering strategies in sustained-remission rheumatoid arthritis: Systematic review and… — Seminars in Arthritis and Rheumatism 2026 3. Temporary Cessation of DMARD Therapy and COVID-19 Supplemental Dose Vaccine Immunogenicity in Patients With Inflammatory Arthritis: The COVER Randomized Clinic… — JAMA Internal Medicine 2026 4. Preclinical and clinical outcomes in patients with high rheumatoid factor levels treated with TNF inhibitors:a systematic review. — Annals of the Rheumatic Diseases 2026 5. Impact of bimekizumab on CANDEN spinal MRI inflammation & structural lesions in radiographic axial spondyloarthritis: 2-year phase 3 results. — Rheumatology 2026 6. Oral glucocorticoid dose patterns and organ damage in systemic lupus erythematosus - a nationwide cohort study. — Arthritis & Rheumatology 2026 7. Belimumab prevention against organ damage over 8 years and safety up to 13 years: three pooled open-label, long-term extension SLE studies. — Lupus Science & Medicine 2026 8. Study on the implementation of the 2015 EULAR/ACR recommendations for polymyalgia rheumatica in clinical practice. — RMD Open 2026 9. CAR T cells for autoimmune diseases: 2026 update of the EBMT-ISCT-JACIE practice harmonisation and consensus recommendations. — Lancet Rheumatology 2026 10. Immune reset in rheumatic autoimmune disease: from a tantalising metaphor to a measurable therapeutic state. — Annals of the Rheumatic Diseases 2026 Listen at https://audioscholar.cc/episode/h37d5f4nht

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning lupus treatment and pro… This week's papers: 1. Clinical and immunological outcomes of rituximab-based, mycophenolate mofetil-based and cyclophosphamide-based treatment strategies for systemic lupus erythema… — RMD Open 2026 2. Risk of new primary cancer, locoregional progression or metastasis associated with bDMARDs and tsDMARDs in patients with rheumatoid arthritis and prior cancer:… — RMD Open 2026 3. Predicting relapse and infection to optimize patient outcomes in ANCA-associated vasculitis: data from the MAINRITSAN trials cohort. — Rheumatology 2026 4. Overall and specific treatment effects of pharmacological interventions for hand osteoarthritis: a systematic review and meta-analysis of randomized controlled… — Osteoarthritis and Cartilage 2026 5. Comparison of four clinical risk prediction models for the diagnosis of giant cell arteritis: results from the ongoing PREDICT-GCA study. — RMD Open 2026 6. Ability of SLE-DAS and SLEDAI-2K to predict damage accrual in SLE: A real-world 7-year cohort study from Sweden. — Rheumatology 2026 7. Management strategies for articular flares during biologic therapy in non-systemic polyarticular JIA: a multicentre study. — Rheumatology 2026 8. Cellular and proteomic changes following administration of peresolimab in patients with rheumatoid arthritis: a post-hoc analysis of a randomised phase 2a tria… — Lancet Rheumatology 2026 9. Pulmonary hypertension in anti-synthetase syndrome: prevalence, comparative risk across autoimmune diseases, and impact on survival. — Rheumatology 2026 10. DNA methylation signatures distinguish gout from asymptomatic hyperuricaemia and converge with genetic risk at immune-metabolic loci. — Annals of the Rheumatic Diseases 2026 Listen at https://audioscholar.cc/episode/dyjrs3gv76

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning vasculitis risk stratif… This week's papers: 1. Estimating 2-year risk of first relapse in ANCA-associated vasculitis: derivation of a risk-prediction model based on participants in the PEXIVAS trial. — Annals of the Rheumatic Diseases 2026 2. Diagnostic accuracy of musculoskeletal ultrasound in suspected polymyalgia rheumatica: a multicentre, cohort study. — Lancet Rheumatology 2026 3. Early mepolizumab initiation during remission induction is associated with lower organ damage burden in EGPA: a multicentre cohort study. — Rheumatology 2026 4. Evaluating a guideline-aligned prednisone threshold within the Lupus Low Disease Activity State (LLDAS): associations with damage accrual. — RMD Open 2026 5. Treat-to-target: LLDAS, DORIS remission, and flare prevention strategies. — Rheumatology 2026 6. Drug-Free Remission in Early Peripheral Spondyloarthritis, including Psoriatic Arthritis: 10-year follow-up from the CRESPA trial. — Arthritis & Rheumatology 2026 7. Relevance of the 2025 ESC guidelines for the diagnosis and management of myocarditis and pericarditis for systemic autoimmune rheumatic diseases. — Lancet Rheumatology 2026 8. Integrated serum proteomics and autoantibody analyses reveal a biomarker signature predictive of flare during biologic tapering in rheumatoid arthritis. — RMD Open 2026 9. Association between initial treatment strategy and progression to difficult-to-treat rheumatoid arthritis (D2T-RA): evidence from a 20-year-old real-world coho… — RMD Open 2026 10. Early SLE may follow a fast comorbidity/multimorbidity trajectory associated with flare burden and glucocorticoid exposure. — RMD Open 2026 Listen at https://audioscholar.cc/episode/5ngs6ep2cw

Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning targeted therapy across spondyloarthritis, lupus and fibromyalgia, the science of measuring and monitoring disease over time, and a cluster of population-level… This week's papers: 1. Impact of Dual Interleukin-17A and Interleukin-17F Inhibition with Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: MRI and Radio… — Arthritis & Rheumatology 2026 2. Efficacy and safety of telitacicept combined with standard of care in patients with proliferative lupus nephritis: a real-world retrospective study. — Lupus Science & Medicine 2026 3. Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial. — Lancet Rheumatology 2026 4. Conceptual framework for the definition of disease modification in systemic sclerosis and potential implications for drug development and clinical study design. — Annals of the Rheumatic Diseases 2026 5. Rheumatoid Arthritis in Adults: A Review. — JAMA 2026 6. Sequential disease activity assessment for predicting future treatment trajectories in patients with rheumatoid arthritis treated with JAK inhibitors: a group-… — Annals of the Rheumatic Diseases 2026 7. Digital home monitoring in patients with juvenile idiopathic arthritis to increase intervals of hospital visits. — Rheumatology 2026 8. Incidence and disease course of polymyalgia rheumatica during two decades: a nationwide study across healthcare sectors in Denmark. — Arthritis & Rheumatology 2026 9. Comorbidity and mortality in adults with juvenile idiopathic arthritis: a nationwide Norwegian register-based matched cohort study. — Rheumatology 2026 10. Mortality and causes of death in patients with Sjögren disease in Western Australia: a population-based study. — Rheumatology 2026 Listen at https://audioscholar.cc/episode/msfddb4nbc

Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning three broad themes: how we define and manage so-called difficult-to-manage disease in spondyloarthritis and psoriatic arthritis, new technology and triage strat… This week's papers: 1. Updated COVID-19 Vaccines and Health Outcomes in Patients With Autoimmune Rheumatic Conditions. — Arthritis & Rheumatology 2026 2. Difficult-to-manage and treatment-refractory psoriatic arthritis in patients treated with biological and targeted synthetic DMARDs: prevalence and characterist… — Annals of the Rheumatic Diseases 2026 3. Incidence, baseline-associated factors and burden of difficult-to-manage axial spondyloarthritis: a 10-year analysis of the DESIR cohort. — RMD Open 2026 4. Performance of a triage approach for identification of patients with inflammatory rheumatic and musculoskeletal diseases among rheumatology referrals. — Annals of the Rheumatic Diseases 2026 5. Automated detection of active and structural MRI lesions in the sacroiliac joints in axial spondyloarthritis: training and validation across 3 phase III clinic… — Annals of the Rheumatic Diseases 2026 6. Efficacy and safety of upadacitinib in anti-TNF-refractory intestinal Behçet's disease: a single-center retrospective study. — Rheumatology 2026 7. AMETHYST: a Retrospective Cohort Study of Treatment Patterns and Outcomes in Patients With Glucocorticoid-refractory Macrophage Activation Syndrome Complicatin… — Arthritis & Rheumatology 2026 8. Selexipag in systemic sclerosis-associated pulmonary arterial hypertension: long-term real-world data from a multicentre Italian cohort. — Rheumatology 2026 9. Validation of systemic Juvenile Arthritis Disease Activity Score 10 in adults with Still's disease. — Annals of the Rheumatic Diseases 2026 10. Therapeutic plasma exchange in pediatric ANCA-associated vasculitis: a multicenter real-world experience. — Rheumatology 2026 Listen at https://audioscholar.cc/episode/usdvyu5rej